Parkinson's Advisory Committee: Nuplazid Review Will Test Targeted Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Acadia's pimavanserin would be first treatment for psychosis related to Parkinson's, but it only succeeded after endpoint was refined in second Phase III trial.